X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Californians with diabetes will have access to Civica’s low-cost insulins via the CalRx Biosimilar Insulin Initiative. Civica will produce three insulins, glargine, lispro and aspart, available both in vials and prefilled pens under the CalRx label.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: Undislcosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: CalRx Biosimilar Insulin Initiative
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Partnership March 18, 2023
Details:
Civica plans to produce three insulin biosimilars – glargine, lispro and aspart – each of which will be available both in vials and prefilled pens, and to ensure redundancy of supply, Ypsomed will provide injector dosing pens from their manufacturing facilities.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Recipient: Ypsomed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 31, 2023
Details:
Abiraterone acetate 250 mg is indicated in combination with prednisone for the treatment of people with metastatic castration-resistant prostate cancer (CRPC) and those with metastatic high-risk castration-sensitive prostate cancer (CSPC).
Lead Product(s): Abiraterone Acetate,Prednisone
Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
Civica will produce three insulins – glargine, lispro and aspart (biologics corresponding to, and interchangeable with, Lantus, Humalog and Novolog respectively) – each of which will be available both in vials and prefilled pens.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Product Name: Insulin Glargine-Generic
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: GeneSys Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 03, 2022
Details:
Sandoz has shipped pantoprazole sodium for injection, 40 mg to Civica Rx to supply the hospitals it serves as part of a multiyear collaboration to help reduce supply shortages, with several other medicines on the way before the end of the year.
Lead Product(s): Pantoprazole Sodium
Therapeutic Area: Gastroenterology Product Name: Pantoprazole Sodium-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2020
Details:
Kaiser Permanente to join as a governing member with the goal of helping to secure supplies of essential generic medications during COVID-19 and beyond.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Recipient: Kaiser Permanente Washington Health Research
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
